Sanofi Q2 FY26 business EPS rises 33.3% to €2.09; net sales climb 17.8% to €11.6 billion
Reuters2026/07/30 05:31- Sanofi Q2 net sales rose 16% to €11.6 billion, while IFRS net income fell 91.3% to €343 million.
- IFRS EPS dropped 91% to €0.29; business EPS climbed 31.4% to €2.09.
- Dupixent sales increased 37.6% to €5.2 billion; vaccines sales declined 4.7% to €1.1 billion on a tough flu comparison.
- Pharma launches sales jumped 48.3% to €1.3 billion; R&D expenses rose 17.9% to €2.2 billion.
- 2026 guidance was raised, with net sales now seen growing around 10% and business EPS expected to grow slightly faster.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
